| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
Human lung adenocarcinoma epithelial (A549) cells, Lewis lung cancer (LLC), and human leukemia (HL-60) cells are all susceptible to cytotoxicity from sophoflavescenol. By preventing nitric oxide synthesis and ROS formation generated by tert-butyl hydroperoxide, sophoflavescenol exhibits strong anti-inflammatory effects in RAW 264.7 cells instead of blocking nuclear factor kappa B activation [1]. With an IC50 value of 0.30 µM, sophoflavescenol strongly inhibits RLAR activity, whereas the well-known ARI epalrestat has an IC50 value of 0.07 µM. With an IC50 value of 0.17 µM, sophoflavescenol also exhibited strong inhibitory activity in the HRAR assay, matching epalrestat's (0.15 µM) value. Sophorol (IC50 17.89 µg/mL) shown greater potency in inhibiting AGE production in the AGE experiment compared to aminoguanidine (IC50 81.05 µg/mL). With IC50 values of 8.37 and 8.21 µM for AChE and BChE, respectively, sophoflavescenol exhibits strong inhibitory effects on both enzymes. Moreover, sophoflavescenol, with an IC50 value of 10.98 µM, demonstrates strong dose-dependent BACE1 inhibition[2]. Sophoflavescenol (Ki=0.005 μM) is a mixed inhibitor of cGMP PDE5. The most selective substance for PDE5 is sophoflavescenol, which is 31.5 times more selective than PDE3 and 196.2 times more selective than PDE4 [3].
|
|---|---|
| ln Vivo |
Sophoflavescenol inhibits tumor growth in LLC tumor models, exhibiting strong in vivo anti-tumor action. In HL-60 cells, it activates caspase-3, inducing apoptosis [1].
|
| References |
|
| Additional Infomation |
Sophoflavescenol has been reported in Albizia julibrissin and Sophora flavescens with data available.
|
| Molecular Formula |
C21H20O6
|
|---|---|
| Molecular Weight |
368.3799
|
| Exact Mass |
368.125
|
| CAS # |
216450-65-6
|
| PubChem CID |
9929189
|
| Appearance |
Solid powder
|
| Density |
1.359±0.06 g/cm3
|
| Boiling Point |
631.8±55.0 °C at 760 mmHg
|
| Melting Point |
273-275 ºC
|
| Flash Point |
226.2±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.657
|
| LogP |
4.62
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
612
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VMLJAWUWVVHRNG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H20O6/c1-11(2)4-9-14-15(23)10-16(26-3)17-18(24)19(25)20(27-21(14)17)12-5-7-13(22)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3
|
| Chemical Name |
3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~67.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.79 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7146 mL | 13.5729 mL | 27.1459 mL | |
| 5 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL | |
| 10 mM | 0.2715 mL | 1.3573 mL | 2.7146 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
